Cargando…

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

BACKGROUND: Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown. This meta‐analysis aimed to clarify the differences in resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Nobuaki, Katakura, Seigo, Kamimaki, Chisato, Somekawa, Kohei, Fukuda, Nobuhiko, Tanaka, Katsushi, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Piao, Hongmei, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017253/ https://www.ncbi.nlm.nih.gov/pubmed/33565276 http://dx.doi.org/10.1111/1759-7714.13878

Ejemplares similares

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
por: Katakura, Seigo, et al.
Publicado: (2020)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
por: Teranishi, Shuhei, et al.
Publicado: (2020)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
por: Katakura, Seigo, et al.
Publicado: (2019)

Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study
por: Hoshi, Miki, et al.
Publicado: (2021)

Clinical features of asthma with connective tissue diseases
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy
por: Chen, Hao, et al.
Publicado: (2022)

Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Elderly sarcoidosis in Japan
por: Masumoto, Nami, et al.
Publicado: (2022)

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
por: Fujii, Hiroaki, et al.
Publicado: (2022)

The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease
por: Nishikawa, Yurika, et al.
Publicado: (2021)

Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases
por: Tagami, Yoichi, et al.
Publicado: (2021)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis
por: Chen, Hao, et al.
Publicado: (2021)

The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy
por: Watanabe, Keisuke, et al.
Publicado: (2021)

＜Editors’ Choice＞ Comparison of clinical features between patients with acute exacerbation of idiopathic interstitial pneumonia and collagen vascular disease-associated interstitial pneumonia
por: Kata, Yuki, et al.
Publicado: (2023)

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis
por: Nakamura, Kazunori, et al.
Publicado: (2023)

Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials
por: Ebina-Shibuya, Risa, et al.
Publicado: (2021)

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
por: Kobayashi, Nobuaki, et al.
Publicado: (2023)

Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
por: Hara, Yu, et al.
Publicado: (2022)

ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
por: Fujii, Hiroaki, et al.
Publicado: (2023)

Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease
por: Inoue, Rei, et al.
Publicado: (2021)

A functionally improved case of obstructive impairment caused by systemic lupus erythematosus
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Assessment of diagnostic utility of serum hemeoxygenase-1 measurement for acute exacerbation of interstitial pneumonias
por: Kata, Yuki, et al.
Publicado: (2022)

Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies
por: Ishii, Mai, et al.
Publicado: (2021)

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax
por: Aoki, Ayako, et al.
Publicado: (2020)

The clinical impact of comorbidities among patients with idiopathic pulmonary fibrosis undergoing anti-fibrotic treatment: A multicenter retrospective observational study
por: Aoki, Ayako, et al.
Publicado: (2023)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Genetic model selection for a case–control study and a meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_giitnuo3rpdjook27dakpvknbv